Chair: Cyrille Cohen, Bar-Ilan University, Israel

08:00 - 08:15
TCR GENE THERAPY TARGETING ‘PUBLIC’ NEOANTIGENS RESULTING FROM COMMON DRIVER ONCOGENES
Chris Klebanoff, Memorial Sloan Kettering Cancer Center, USA

08:15 - 08:30
NEOANTIGEN-SPECIFIC T-CELL RECEPTORS AS PERSONALIZED TOOLS IN THE TREATMENT OF CANCER
Angela Krackhard, Klinikum rechts der Isar, Technical University of Munich, Germany

08:30 - 08:45
PRIMARY STRUCTURE INFLUENCE ON THE EXPRESSION AND FUNCTION OF TCRS, CARS AND CSRS FOR T-CELL IMMUNOTHERAPY
Cyrille Cohen, Bar-Ilan University, Israel

08:45 - 08:55
AS SMALL AS IT CAN BE: SHORT PEPTIDE-DERIVED TARGET MOLECULES FOR REDIRECTION OF UNICAR T-CELLS AND IMAGING OF SSTR2-EXPRESSING CANCERS
Liliana Loureiro, German Cancer Research Center, Germany

08:55 - 09:20
Discussion

Chair: Adi Barzel, Tel-Aviv University, Israel

09:20 - 09:50
ADAPTOR UNICAR AND REVCAR PLATFORMS FOR FLEXIBLE, SWITCHABLE AND COMBINATORIAL TUMOR TARGETING
Anja Feldmann, Helmholtz-Center Dresden-Rossendorf, Dresden, Germany

09:50 - 10:20
T CELL METABOLIC PROFILING – THE NEXT LEVEL
Daniel Gebhard, Agilent Technolgies, Germany

10:25 - 10:40
SIMPLE DETECTION AND ISOLATION OF CAR CELLS DIRECTLY FROM PATIENT SAMPLES
Jessica Mrugala, Miltenyi Biotec, Germany

10:40 - 10:55
RISK MITIGATION STRATEGIES FOR CRITICAL RAW MATERIALS IN CELL THERAPY MANUFACTURING
Gonçalo Regalo, Fujifilm Irvine Scientific, Portugal

Chair: Paolo Dellabona, San Raffaele Scientific Institute, Italy

11:00 - 11:20
ENGINEERING INKT CELLS FOR DUAL TARGETING OF CANCER AND SUPPRESSIVE MYELOID CELLS
Paolo Dellabona, San Raffaele Scientific Institute, Italy

11:20 - 11:40
THERAPEUTIC POTENTIAL OF INVARIANT NATURAL KILLER T CELLS MODIFIED WITH CD38 OR BCMA CHIMERIC ANTIGEN RECEPTORS FOR MULTIPLE MYELOMA
Tuna Mutis, Amsterdam University Medical Center, Netherlands

11:40 - 11:55
B CELL ENGINEERING FOR THE PREVENTION AND TREATMENT OF DISEASE
Julia McKechnie, Fred Hutchinson Cancer Research Center, USA

11:55 - 12:20
Discussion

12:20 - 12:35
WELCOME AND INTRODUCTION
Martin Dreyling, Ludwig-Maximilians-University Hospital, Germany

12:25 - 12:48
CAR T CELL THERAPY FOR THE TREATMENT OF AGGRESSIVE B-NHL
Christian Schmidt, Ludwig-Maximilians-University Hospital, Germany

12:48 - 13:11
CAR T CELL THERAPY FOR THE TREATMENT OF MULTIPLE MYELOMA
Sophia Danhof, University Hospital Wuerzburg, Germany

13:11 - 13:20
Discussion and Closing remarks

13:40 - 13:55
HIGHLY MULTIPLEXED SINGLE-CELL FUNCTIONAL PROFILING OF CAR-T CELLS ENABLES MORE PREDICTIVE PRODUCT CHARACTERIZATION AND PROVIDES A CRITICAL QUALITY METRIC FOR THE POTENCY OF CELL THERAPY
Mourad Ferhat,Isoplexis, France

13:55 - 14:10
SIMPLIFYING THE PATH TO RAPID, RELIABLE TRANSLATION OF CELL MANUFACTURING THROUGH PLATFORM, PROCESS, AND PRODUCT CONTINUITY BEGINNING WITH THE G-REX BIOREACTOR
Jenny Stjernberg, ScaleReady, Sweden

14:10 – 14:20
FUNCTIONAL PHENOMICS ENABLING MULTIMODAL ANALYSIS OF CELL-CELL INTERACTIONS IN A 3D MICROENVIRONMENT AT SINGLE-CELL RESOLUTION
Stephan Brockmann, evorion biotechnologies GmbH, Germany

Chair: Tobias Feuchtinger, Ludwig-Maximilians-University, Germany

14:30 - 14:55
KEYNOTE LECTURE: ENHANCING THE FUNCTIONAL PERSISTENCE AND ANTIGEN SENSITIVITY OF CAR T CELLS
Michel Sadelain, Memorial Sloan Kettering Cancer Center, USA

14:55 - 15:10
ADOPTIVE TRANSFER OF VIRUS-SPECIFIC T CELLS IN THE IMMUNOCOMPROMISED HOST
Tobias Feuchtinger, Ludwig-Maximilians-University, Germany

15:10 - 15:25
SIGNALING AND CYTOKINE ENGINEERING OF CAR-T CELLS
Gianpietro Dotti, University of North Carolina Lineberger Comprehensive Cancer Center, USA

15:25 - 15:40
NOVEL MANUFACTURING TECHNOLOGIES THAT ENABLE ADVANCED T CELL GENERATION
Mateusz Poltorak, Juno Therapeutics GmbH, a Bristol Myers Squibb Company, Germany

15:40 - 16:10
Discussion

16:15 - 16:43
E-POSTER SESSION 2: ENGINEERED T CELL THERAPY FOR SOLID TUMORS

Chair: Tal Akriv, Tel Aviv University, Israel

16:15 - 16:22
BOOSTING CAR T CELL EFFICACY BY MODULATION OF THE TUMOR MICROENVIRONMENT IN GLIOBLASTOMA
Ignacio Mastandrea, Tel Aviv University, Israel

16:22 - 16:29
UNICAR CAR T CELL THERANOTICS FOR DIAGNOSTIC IMAGING AND THERAPY OF PROSTATE CANCER
Claudia Arndt, Helmholtz Center Dresden-Rossendorf, Germany

16:29 - 16:36
TARGETING THE EXTRA DOMAIN A FROM FIBRONECTIN FOR CANCER THERAPY WITH CAR-T CELLS
Celia Martín-Otal, Center For Applied Medical Research (CIMA), Spain

16:36 - 16:43
EPITOPE SPREADING DRIVEN BY THE JOINT ACTION OF CAR T CELLS AND PHARMACOLOGICAL STING STIMULATION COUNTERACTS TARGET ANTIGEN ESCAPE
Sandra Hervas-Stubbs, Foundation for Applied Medical research, Spain

Chair: Michael Bachmann, Helmholtz Center Dresden-Rossendorf, Germany

16:50 - 17:15
KEYNOTE LECTURE: FRATRICIDE AS AN ENABLER OF UNIVERSAL T CELL THERAPY
“WAS MICH NICHT UMBRINGT, MACHT MICH STÄRKER``
Malcolm Brenner, Baylor College of Medicine, USA

17:15 - 17:30
INCREASING THE SAFETY OF CAR TECHNOLOGY: GATED TARGETING WITH MODULAR CARS
Michael Bachmann, Helmholtz Center Dresden-Rossendorf, Germany

17:30 - 17:45
CRISPR CUT AND UNCUT CAR T CELLS FOR LEUKAEMIA
Waseem Qasim, University College London, UK

17:45 - 18:05
Discussion

Chair: Dirk Busch, Technical University of Munich, Germany

18:05 - 18:20
T CELL THERAPY FOR VIRUSES
Ann Leen, Baylor College of Medicine, USA

18:20 - 18:35
ORTHOTOPIC TCR REPLACEMENT ENABLES GENERATION OF PREDICTABLE ANTIGEN-SPECIFIC T CELL PRODUCTS
Dirk Busch, Technical University of Munich, Germany

18:35 - 18:50
IN VIVO  ENGINEERED B CELLS RETAIN MEMORY AND SECRETE HIGH TITERS OF ANTI-HIV ANTIBODIES IN MICE
Adi Barzel, Tel-Aviv University, Israel

18:50 - 19:05
CAR-TREG PROGRAMS TARGETING TRANSPLANTATION, INFLAMMATION AND AUTOIMMUNITY
Maurus de la Rosa, Sangamo Therapeutics, France

19:05 - 19:30
Discussion

Chair: Michael Hudecek, Hospital of the University of Würzburg, Germany

08:00 - 08:25
NEXT GENERATION NDM NANO VECTORS – AN ALTERNATIVE VECTOR PLATFORM FOR THE SAFE, RAPID AND PERSISTENT MANUFACTURE OF RECOMBINANT T CELLS FOR AUTOLOGOUS T CELL IMMUNOTHERAPY
Richard Harbottle, German Cancer Research Centre, Germany

08:25 - 08:40
NOVEL TARGETS AND TECHNOLOGIES FOR CAR T-CELL THERAPY
Michael Hudecek, Hospital of the University of Würzburg, Germany

08:40 - 08:50
FREQUENT CRISPR-CAS9 INDUCED ANEUPLOIDY IN PRIMARY HUMAN T CELLS
Alessio Nahmad, Tel Aviv University, Israel

08:50 - 09:05
PIGGYBAC TRANSPOSON-MEDIATED CAR-T CELLS: A PROMISING AND REALISTIC APPROACH FOR CLINICAL APPLICATION
Shigeki Yagyu, Kyoto Prefectural University of Medicine, Japan

09:05 - 09:25
Discussion

Chair: Adi Barzel, Tel-Aviv University, Israel

09:25 - 09:27
Introduction

09:27 - 09:34
DEVELOPMENT AND EVALUATION OF NEXT GENERATION IL-15 COENGINEERED MURINE CAR-T CELLS
Evripidis Lanitis, UNIL/Ludwig Cancer Institute Lausanne, Switzerland

09:34 - 09:41
ORTHOGONAL GENE ENGINEERING ENABLES CD8+ T CELLS TO CONTROL TUMORS THROUGH A NOVEL TOX-INDIFFERENT SYNTHETIC EFFECTOR STATE
George Coukos, Lausanne University Hospital, Switzerland

09:41 - 09:48
A UNIQUE ENGINEERED T CELL ENABLES ANTIBODY-MEDIATED CYTOTOXICITY OVERCOME THE LIMITATIONS OF CAR T CELL THERAPY AGAINST SOLID TUMORS
Yaron Carmi, Tel Aviv University, Israel

09:48 - 09:55
OVERCOMING T CELL DYSFUNCTION IN ACIDIC PH TO ENHANCE ADOPTIVE T CELL TRANSFER IMMUNOTHERAPY
Flor Navarro, Center For Applied Medical Research (CIMA), Spain

09:55 - 10:02
GENOME-SCALE SCREEN FOR SYNTHETIC DRIVERS OF T-CELL PROLIFERATION
Mateusz Legut, New York Genome Center, USA

10:02 - 10:09
ADVANCED VIRAL VECTORS OVERCOME MAJOR HURDLE TOWARDS LYMPHOPREPLETE MOUSE MODELS FOR IN VIVO CAR THERAPY THROUGH RECEPTOR TARGETING
Alexander Michels, Paul-Ehrlich-Institut, Germany

10:09 - 10:16
GENE-TRANSFER METHODOLOGY AFFECTS CHIMERIC ANTIGEN RECEPTOR EXPRESSION AND REGULATION IN T-CELLS, AND DETERMINES ANTITUMOR POTENCY IN THE CONTEXT OF HIGH VS. LOW TARGET ANTIGEN DENSITY
Leon Gehrke, University Hospital Wuerzburg, Germany

10:16 - 10:23
HUMAN T CELLS ENGINEERED WITH A LEUKEMIA LIPID-SPECIFIC TCR ENABLES DONOR-UNRESTRICTED RECOGNITION OF CD1C-EXPRESSING LEUKEMIA
Michela Consonni, San Raffaele Scientific Institute, Italy

10:23 - 10:25
Summary

10:30 - 10:58
E-POSTER SESSION 3: NEW APPROACHES IN LYMPHOCYTE ENGINEERING & OTHER

Chair: Elvira D’Ippolito, Technical University of Munich, Germany

10:30 - 10:37
ENGINEERING AVIDCARS FOR SMALL MOLECULE-DEPENDENT CAR T CELL REGULATION
Michael Traxlmayr, University of Natural Resources and Life Sciences, Austria

10:37 - 10:44
NANOPARTICLE-SENSITIZED PHOTOPORATION AS AN EMERGING NON-VIRAL ALTERNATIVE FOR T CELL ENGINEERING WITH NUCLEIC ACIDS
Dominika Berdecka, University of Ghent, Belgium

10:44 - 10:51
A NOVEL TUMOR MODEL FOR THE STUDY OF CELLULAR IMMUNOTHERAPY USING HUMANIZED MICE
Juliane Mietz, University Of Zurich, Switzerland

10:51 - 10:58
FUNCTIONAL CRISPR DISSECTION OF GENE NETWORKS CONTROLLING HUMAN REGULATORY T CELL IDENTITY
Kathrin Schumann, Institute for Med. Microbiology, Immunology and Hygiene, Germany

Chair: Hinrich Abken, Regensburg Center for Interventional Immunotherpay, Germany

11:00 - 11:25
KEYNOTE LECTURE: GENE-BASED DELIVERY OF IMMUNOSTIMULANT CYTOKINES REPROGRAMS THE TUMOR MICROENVIRONMENT AND SYNERGIZES WITH CAR-T CELL THERAPY
Luigi Naldini, San Raffaele Telethon Institute for Gene Therapy, Italy

11:25 - 11:40
CARS AND TRUCKS AND THE NEXT GENERATION CAR T CELLS
Hinrich Abken, Regensburg Center for Interventional Immunotherapy, Germany

11:40 - 12:05
AUTOMATED AND SCALABLE CLOSED-SYSTEM PLATFORM FOR CELL ISOLATION AND ACTIVATION
Øystein Åmellem, Thermo Fisher Scientific, Norway

12:05 - 12:15
CHARACTERIZATION OF A NOVEL RADIOHAPTEN CAPTURE SYSTEM IN CAR T CELLS FOR TRACKING IN VIVO AND IMPROVING CAR T EFFICACY
Keifer Kurtz, Memorial Sloan Kettering, USA

12:20 - 12:30
RESISTANT MECHANISM OF NHL TO CART THERAPY
Weidong Han, Chinese PLA General Hospital, China

12:30 - 12:50
Discussion

Moderators: Adi Barzel, Tel-Aviv University, Israel
Dirk Busch, Technical University of Munich, Germany

Panelists:
Stan Riddell, Fred Hutchinson Cancer Research Center, USA
Luigi Naldini, San Raffaele Telethon Institute for Gene Therapy, Italy
Malcolm Brenner, Baylor College of Medicine, USA